JUBLPHARMA — Jubilant Pharmova Cashflow Statement
0.000.00%
- IN₹143.73bn
- IN₹161.51bn
- IN₹67.03bn
- 96
- 23
- 84
- 80
Annual cashflow statement for Jubilant Pharmova, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 12,105 | 8,711 | 6,304 | 278 | 1,705 |
Depreciation | |||||
Non-Cash Items | 2,988 | 6,058 | 1,978 | 2,288 | 3,735 |
Discontinued Operations | |||||
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4,283 | -2,212 | -3,724 | -1,500 | 454 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 15,429 | 17,073 | 8,375 | 6,607 | 9,713 |
Capital Expenditures | -5,742 | -5,275 | -6,000 | -8,144 | -8,977 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 2,472 | -2,115 | 2,196 | 2,700 | 2,898 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -3,270 | -7,390 | -3,804 | -5,444 | -6,079 |
Financing Cash Flow Items | -3,250 | -2,922 | -1,349 | -2,342 | -2,437 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -10,504 | -17,094 | -326 | -1,567 | -4,325 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2,254 | -7,289 | 4,819 | 301 | -575 |